Research Paper Volume 13, Issue 14 pp 18870—18878

Atorvastatin attenuates intermittent hypoxia-induced myocardial oxidative stress in a mouse obstructive sleep apnea model

class="figure-viewer-img"

Figure 3. Differences in oxidative stress markers in myocardial tissue between groups. In comparison to normoxia + vehicle group, myocardial tissue of mice in the CIH + vehicle group had higher MDA levels (23.54 ± 5.39 vs. 31.25 ± 4.44, p < 0.001) and lower SOD activity (66.10 ± 12.34 vs. 28.68 ± 13.91, p < 0.001) and T-AOC levels (15.35 ± 2.45 vs. 12.35 ± 2.15, p < 0.05). Atorvastatin significantly decreased MDA levels (23.58 ± 3.68 in CIH + atorvastatin group vs. 31.25 ± 4.44 in CIH + vehicle group, p < 0.001) and increased SOD activity (61.35 ± 17.13 in CIH + atorvastatin group vs. 28.68 ± 13.91 in CIH + vehicle group, p < 0.001) and T-AOC levels (16.35 ± 2.37 in CIH + atorvastatin group vs. 12.35 ± 2.15 in CIH + vehicle group, p < 0.01) in IH-induced mice (A, B, and C). Nrf2 levels were lower in the CIH + vehicle group than in the normoxia + vehicle group (0.41 ± 0.25 vs. 0.87 ± 0.32, p < 0.05), and atorvastatin treatment increased Nrf2 levels in CIH mice (1.02 ± 0.64 vs. 0.41 ± 0.25, p < 0.01) (D).